1 week Ago By ABMN Staff
KLP Kapitalforvaltning AS purchased a new position in shares of ORIC Pharmaceuticals, Inc. ( NASDAQ:ORIC – Free Report ) in the 4th quarter, Holdings Channel.com reports.
The institutional investor purchased 6,200 shares of the company’s stock, valued at approximately $50,000. Other large investors also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc.
lifted its holdings in ORIC Pharmaceuticals by 152.7% during the third quarter. Charles Schwab Investment Management Inc.
now owns 410,229 shares of the company’s stock valued at $4,205,000 after purchasing an additional 247,863 shares during the last quarter. Verition Fund Management LLC lifted its stake in shares of ORIC Pharmaceuticals by 25.6% during the 3rd quarter.
Verition Fund Management LLC now owns 42,980 shares of the company’s stock valued at $441,000 after buying an additional 8,752 shares in the last quarter. Wellington Management Group LLP boosted its holdings in ORIC Pharmaceuticals by 42.0% in the 3rd quarter.
Wellington Management Group LLP now owns 174,388 shares of the company’s stock worth $1,787,000 after buying an additional 51,565 shares during the period. Barclays PLC boosted its holdings in shares of ORIC Pharmaceuticals by 111.2% in the third quarter.
Barclays PLC now owns 107,261 shares of the company’s stock worth $1,100,000 after acquiring an additional 56,474 shares during the period. Finally, M&T Bank Corp raised its stake in shares of ORIC Pharmaceuticals by 19.2% during the 3rd quarter.
M&T Bank Corp now owns 85,137 shares of the company’s stock valued at $873,000 after purchasing an additional 13,711 shares during the period. Hedge funds and other institutional investors own 95.05% of the company’s stock.
Analyst Ratings Changes A number of research analysts have weighed in on the company. Guggenheim reaffirmed a “buy” rating on shares of ORIC Pharmaceuticals in a report on Wednesday, February 26th. JPMorgan Chase & Co.
boosted their price objective on shares of ORIC Pharmaceuticals from $21.00 to $22.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th.
Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ORIC Pharmaceuticals in a report on Tuesday, January 14th. Wedbush reissued an “outperform” rating and set a $20.00 price objective on shares of ORIC Pharmaceuticals in a research note on Thursday, March 20th.
Finally, HC Wainwright restated a “buy” rating and issued a $21.00 target price on shares of ORIC Pharmaceuticals in a research note on Friday, February 21st. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.
com, ORIC Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $18.86. ORIC Pharmaceuticals Trading Up 14.
2 % Shares of ORIC Pharmaceuticals stock opened at $4.92 on Friday. The firm has a market capitalization of $349.
45 million, a PE ratio of -2.70 and a beta of 1.38.
ORIC Pharmaceuticals, Inc. has a 12 month low of $3.90 and a 12 month high of $14.
67. The business’s 50-day moving average price is $7.40 and its 200-day moving average price is $8.
67. ORIC Pharmaceuticals ( NASDAQ:ORIC – Get Free Report ) last announced its quarterly earnings data on Tuesday, February 18th. The company reported ($0.
51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.01.
As a group, analysts predict that ORIC Pharmaceuticals, Inc. will post -2.17 earnings per share for the current fiscal year.
About ORIC Pharmaceuticals ( Free Report ) ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. Featured Stories Want to see what other hedge funds are holding ORIC? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for ORIC Pharmaceuticals, Inc. ( NASDAQ:ORIC – Free Report ). Receive News & Ratings for ORIC Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ORIC Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
